Tag Archives: NASDAQ:XLRN

H.C. Wainwright Sticks to Its Buy Rating for Acceleron Pharma (XLRN)

H.C. Wainwright analyst Edward White maintained a Buy rating on Acceleron Pharma (XLRN – Research Report) today and set a price target of $72. The company’s shares closed on Friday at $52.93. White said: “Our $72 price target is based

Acceleron Pharma (XLRN) Gets a Hold Rating from Oppenheimer

Oppenheimer analyst Leah R. Cann maintained a Hold rating on Acceleron Pharma (XLRN – Research Report) today. The company’s shares opened today at $52.14. Cann observed: “While we have not modeled ACE-083 into our outlook for Acceleron by 2022, having

Oppenheimer Maintains a Hold Rating on Acceleron Pharma (XLRN)

Oppenheimer analyst Leah R. Cann maintained a Hold rating on Acceleron Pharma (NASDAQ: XLRN) yesterday. The company’s shares closed yesterday at $48.13. Cann noted: “Loss per share was $0.63 compared to our estimated loss of $0.57. The slightly higher than

Acceleron Pharma (XLRN) Receives a Hold from Morgan Stanley

In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Acceleron Pharma (NASDAQ: XLRN), with a price target of $55. The company’s shares closed on Friday at $51.05, close to its 52-week high of $54.34.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Acceleron Pharma (NASDAQ: XLRN), Acelrx (NASDAQ: ACRX) and MannKind (NASDAQ: MNKD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Acceleron Pharma (NASDAQ:XLRN), Acelrx (NASDAQ:ACRX) and MannKind (NASDAQ:MNKD). Acceleron Pharma (XLRN) H.C. Wainwright analyst Edward White maintained a Buy rating on Acceleron Pharma

H.C. Wainwright Releases a Buy Rating on Acceleron Pharma

In a report released today, Edward White from H.C. Wainwright assigned a Buy rating to Acceleron Pharma (NASDAQ: XLRN), with a price target of $74. The company’s shares opened today at $46.74. White noted: “We base our $74 price target